Cargando…

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey

PURPOSE: The current standard of care for surgically eligible stage I non-small cell lung cancer (NSCLC) is surgical resection, but emerging data suggest that stereotactic body radiation therapy (SBRT) is potentially as effective as surgery. However, specialist views of the current evidence about SB...

Descripción completa

Detalles Bibliográficos
Autores principales: Lammers, Austin, Mitin, Timur, Moghanaki, Drew, Thomas, Charles R., Timmerman, Robert, Golden, Sara E., Thakurta, Sujata, Dziadziuszko, Rafal, Slatore, Christopher G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000198/
https://www.ncbi.nlm.nih.gov/pubmed/29904736
http://dx.doi.org/10.1016/j.adro.2018.01.001
_version_ 1783331640247844864
author Lammers, Austin
Mitin, Timur
Moghanaki, Drew
Thomas, Charles R.
Timmerman, Robert
Golden, Sara E.
Thakurta, Sujata
Dziadziuszko, Rafal
Slatore, Christopher G.
author_facet Lammers, Austin
Mitin, Timur
Moghanaki, Drew
Thomas, Charles R.
Timmerman, Robert
Golden, Sara E.
Thakurta, Sujata
Dziadziuszko, Rafal
Slatore, Christopher G.
author_sort Lammers, Austin
collection PubMed
description PURPOSE: The current standard of care for surgically eligible stage I non-small cell lung cancer (NSCLC) is surgical resection, but emerging data suggest that stereotactic body radiation therapy (SBRT) is potentially as effective as surgery. However, specialist views of the current evidence about SBRT and how they would incorporate a randomized controlled trial (RCT) into practice is unclear. We sought to understand specialist opinions about evidence regarding treatment of stage I NSCLC and how this translates into practice and clinical trial implementation. METHODS AND MATERIALS: We used a 28-item, web-based survey that invited all participating providers from the American Society for Radiation Oncology, American Thoracic Society Thoracic Oncology Assembly, and the International Association for the Study of Lung Cancer to share opinions regarding practice beliefs, treatment of stage I NSCLC, and a clinical trial scenario. RESULTS: A total of 959 surveys were completed; 64% were from radiation oncologists (ROs) and 49% were from outside the United States. The majority of ROs (80%) reported that current evidence indicates that SBRT has the same or a better benefit compared with surgery for surgically eligible patients with stage I NSCLC; 28% of non–radiation oncologists (NROs) indicated the same (P < .01). Almost all ROs (94%), compared with 62% of NROs, would permit surgically eligible patients to enroll in an RCT of SBRT versus surgery (P < .01). Most ROs (82%) and NROs (87%) believed that changing practice in thoracic surgery would be somewhat difficult, very difficult, or impossible (P = .066) even if an RCT showed better survival with SBRT. CONCLUSIONS: NROs believe that SBRT is much less effective than surgery, contrary to ROs, who believe that they are similar. Most would support an RCT, but NROs would do so less. Changes in surgical practice may be challenging even if an RCT shows better mortality and quality of life with SBRT. These results are helpful in the creation and dissemination of RCTs that are designed to understand this question.
format Online
Article
Text
id pubmed-6000198
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60001982018-06-14 Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey Lammers, Austin Mitin, Timur Moghanaki, Drew Thomas, Charles R. Timmerman, Robert Golden, Sara E. Thakurta, Sujata Dziadziuszko, Rafal Slatore, Christopher G. Adv Radiat Oncol Lung Cancer PURPOSE: The current standard of care for surgically eligible stage I non-small cell lung cancer (NSCLC) is surgical resection, but emerging data suggest that stereotactic body radiation therapy (SBRT) is potentially as effective as surgery. However, specialist views of the current evidence about SBRT and how they would incorporate a randomized controlled trial (RCT) into practice is unclear. We sought to understand specialist opinions about evidence regarding treatment of stage I NSCLC and how this translates into practice and clinical trial implementation. METHODS AND MATERIALS: We used a 28-item, web-based survey that invited all participating providers from the American Society for Radiation Oncology, American Thoracic Society Thoracic Oncology Assembly, and the International Association for the Study of Lung Cancer to share opinions regarding practice beliefs, treatment of stage I NSCLC, and a clinical trial scenario. RESULTS: A total of 959 surveys were completed; 64% were from radiation oncologists (ROs) and 49% were from outside the United States. The majority of ROs (80%) reported that current evidence indicates that SBRT has the same or a better benefit compared with surgery for surgically eligible patients with stage I NSCLC; 28% of non–radiation oncologists (NROs) indicated the same (P < .01). Almost all ROs (94%), compared with 62% of NROs, would permit surgically eligible patients to enroll in an RCT of SBRT versus surgery (P < .01). Most ROs (82%) and NROs (87%) believed that changing practice in thoracic surgery would be somewhat difficult, very difficult, or impossible (P = .066) even if an RCT showed better survival with SBRT. CONCLUSIONS: NROs believe that SBRT is much less effective than surgery, contrary to ROs, who believe that they are similar. Most would support an RCT, but NROs would do so less. Changes in surgical practice may be challenging even if an RCT shows better mortality and quality of life with SBRT. These results are helpful in the creation and dissemination of RCTs that are designed to understand this question. Elsevier 2018-01-31 /pmc/articles/PMC6000198/ /pubmed/29904736 http://dx.doi.org/10.1016/j.adro.2018.01.001 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Lung Cancer
Lammers, Austin
Mitin, Timur
Moghanaki, Drew
Thomas, Charles R.
Timmerman, Robert
Golden, Sara E.
Thakurta, Sujata
Dziadziuszko, Rafal
Slatore, Christopher G.
Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
title Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
title_full Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
title_fullStr Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
title_full_unstemmed Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
title_short Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
title_sort lung cancer specialists' opinions on treatment for stage i non-small cell lung cancer: a multidisciplinary survey
topic Lung Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000198/
https://www.ncbi.nlm.nih.gov/pubmed/29904736
http://dx.doi.org/10.1016/j.adro.2018.01.001
work_keys_str_mv AT lammersaustin lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT mitintimur lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT moghanakidrew lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT thomascharlesr lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT timmermanrobert lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT goldensarae lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT thakurtasujata lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT dziadziuszkorafal lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey
AT slatorechristopherg lungcancerspecialistsopinionsontreatmentforstageinonsmallcelllungcanceramultidisciplinarysurvey